Google TrendMAX CASTER (200+) — Moose Def. Max Caster At TNA Bound For Glory 2026
The 24/7 Global Portal

World News, Markets & Google Trends

Aggregated real-time headlines, trending Google search queries, and verified dispatches in one single page.

Category:All HeadlinesWorld & GeopoliticsMarkets & EconomyTech & AIPoliticsSearch results for: "Prostate Cancer Stage Inc" (30 stories)

Top Headline Story

MRI vs DRE Prostate Cancer Staging Yields Similar MFS Prognostication
Lead StoryRenal and Urology Newsgeneral
Jul 31

MRI vs DRE Prostate Cancer Staging Yields Similar MFS Prognostication

<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxOTV9CeEpqaHhzZUdJR0JGQWFRZEI3RFJ6a0VPd291TDUyM1E4ZGlhaUdHMVAyQzdXU1lUQkhhMXlLSkZMNU1aU1prdWtBTm1IcnBKZFpySE9PRHVOYjdDV1NRbm9OV3RnYU1Weld2eU9ERC1JUWVhSXJyelNvTHZlUTNIUW5ubjVIeWJGY180bWNCNGEzMkt0Z25WVUpERm5CNy1QRzR0NA?oc=5" target="_blank">MRI vs DRE Prostate Cancer Staging Yields Similar MFS Prognostication</a>  <font color="#6f6f6f">Renal and Urology News</font>

Real-time search volume
200+22m ago

max caster

Moose Def. Max Caster At TNA Bound For Glory 2026

200+22m ago

prince harry family photo story

Prince Harry Reveals the Photo He Took of Archie and Lilibet That ‘Fills My Heart’

500+32m ago

kelley knockel

1 dead, multiple injured after pair of motorcycle crashes involving deer in Iowa

200+32m ago

torino vs udinese

Torino vs Udinese: Italian Serie A stats & head-to-head

Search Results for "Prostate Cancer Stage Inc"

Updated every 3 minutes via FreeNewsApi, GNews, Currents API & Google News

29 stories displayed
Metastatic Prostate Cancer Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
StreetInsidertech

Metastatic Prostate Cancer Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

<a href="https://news.google.com/rss/articles/CBMipAJBVV95cUxPZk9lN04wNVh5RGtYZ21ObGxpbXZydHVoUkVLS0dQbFZYYmM0LXVmX2F0cG5fRTlldFpsaHlWTFlTNDU0S3E1QWZwdzJOMVpCVDFYeml2RmE5cmFxTkFEZVpNQm4yMzVGa0NmS1RPOFByMXNYNkUxMG16V21SdmhFVUNFTnNLNE45S0ZSdml6d1FNZlpKSVJPTWdBRHR5by15WkdmU2o4WTg1MlNpZXNLTXhhT1M0czYwajVGTXRMbXF1d1lOUF9DY2M4Y1lCTmhXMjNtdG5kQWFDT0pCMHdDc3ZHMFlWS1lnYl9UV3NaLWdic0tSN3VKWGpUS1dnZDhTOFdyQXN6UFdZUWtiT19GNVh3c0dMWGF5d1FPSjNkUUIzekE5?oc=5" target="_blank">Metastatic Prostate Cancer Clinical Trial Pipeline Gains Momentum: 80+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight</a>  <font color="#6f6f6f">StreetInsider</font>

AI extracts 2.7M cancer staging records from notes
Truvetatech

AI extracts 2.7M cancer staging records from notes

<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNV1liOWJyZk9fMkdqa0NlTG9ZNnRIeklXeXQybTV3ZDdPLWFOeDViRFNWSDZfY0ZCXzlrbUhHZm1Lam1rZW1vX3EyM0pUU1MtRGY2LUNHWEFUS2FNSjN2cGd6aVd0aEl1YVNPYl9KdnRMeW5OaEFkYkhxS04tNHhLV0tLQlZuOEt6WFE?oc=5" target="_blank">AI extracts 2.7M cancer staging records from notes</a>  <font color="#6f6f6f">Truveta</font>

China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer
PR Newswireworld

China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMirAJBVV95cUxPclo5QW9tb2x2X2wwM2d2ZkJ5NXNJRktJUXgzR0hhMjVqUHNGNk03WEZYajMybFNsUUpHSWYweWVIY2tXejN3eVA3RUZkejdEYTh4NGlfRmlZdzgwZF9GdGdCM3g5WjU1R2Y2Y3QyVno0UTRkTERRdDI3QW5falpNY3RvWE5XTkFwWlhCamVpVVVyRmdSdm44b09ZUW13WkcyR05kVnVkLWlodzVXSkdXT1ZjTGh4SW84VnJicjlxcmlUaVd0OTEydnZySUJUTWFxTE90YnBKY0p6VFdtQnJrbzQ0RnpqTGx0SXRYVElYWkVGTGowMExtdFR2ZU5Jd1JvSElnYS1GMmNramFvTWxpM0t0ZElQRGJQM0wxbmV1azBBb0oteDVwTXNLUUc?oc=5" target="_blank">China NMPA Grants IND Clearance to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for the Treatment of Late-Stage Solid Tumors, Including Prostate Cancer</a>  <font color="#6f6f6f">PR Newswire</font>

Pfizer's prostate cancer drug combination gets US FDA priority review
Reutersgeneral

Pfizer's prostate cancer drug combination gets US FDA priority review

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxPUjI4VHBuUkcxNU9iMkQ4eE5oWmJXblI1S0pRcTZWMWtGY1hqbFhaelVwR0Z4MFFkbHdqTlRULVItTXluWXpMV1hRRmVFd1B2dmNKdDdUZUxNRE15SHp1anJaVVBGdDc0NnV3bS1GaDA5clkzYkM1by1qVi1BdG9hdlJSeV8wUTJxVmpuc2UtTEV3anR2VjZ4bUJ3OVFwUTkyN1l2TVdyYTdmYWJsX1J2MUZPTmVLYzh2R0dHLUZ3?oc=5" target="_blank">Pfizer's prostate cancer drug combination gets US FDA priority review</a>  <font color="#6f6f6f">Reuters</font>

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Yahoo Financetech

Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMirAFBVV95cUxNaUw5aXBwRENsUlkweG85clZ5X1U2U1ZIemZ0U3UtZXB5aDc5NThSVTdKdHZILUYyclVtcWE5RHpWNHJ0V1FNS1piMjlidkNpZThpZHh4ZFM1bTJSWUVPT3ZOXzFMZ1dadWdxR1M4bjQtWm9BQ1ZhdmJmbFZnZzJuMjBhYm5McnhqTnJqVTF0X0NMU1hscURjRDE1YnBsYzNHZmJ4dVZSOThHUFdH?oc=5" target="_blank">Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer</a>  <font color="#6f6f6f">Yahoo Finance</font>

Cleveland Diagnostics Launches 4th Annual PSA on PSA Prostate Cancer Campaign
BioSpacetech

Cleveland Diagnostics Launches 4th Annual PSA on PSA Prostate Cancer Campaign

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxNU0FlRURZSl81b1gyc3Z6bmV5UkpJQ19QREFHeGs5VENtSXJUN1pQM2lLQ0xiNFdOQ2RFdDVvUUZUeVdlSl93b1RoaWt1STIycTVLRl9yNUdmRUw5Z2xsX19lc3RuNUxESWZhRm5USVE4WDMwTFlLWldhRTR1N2swZXl4WG5weGZvRjBuTFprZ0k1eFczNVRfMXVCQjgxaFZHQm8wbEl6QUtlVW9VZnBNMy1fOE1ZTTdQ?oc=5" target="_blank">Cleveland Diagnostics Launches 4th Annual PSA on PSA Prostate Cancer Campaign</a>  <font color="#6f6f6f">BioSpace</font>

FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy
Stock Titangeneral

FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy

<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxOUGVqeC1FTm1XcFlXeW9oNndUX3hJaExoS1h6UDJoaG92bWVxb1J0RG9zTFB0NDdUMi1Ucy1yRTZWUlpqTXdEdkp6RjlLQkxLUlIyWGk4R2pIWjNfd3Zqc2NmMXpXRk56NUVQeEY3cXhzY2VkWmt6eTcxMkMtQUpxcWVSb0hveEZpRkhidTFLX1U1UFhjR1hMSGhOenlHaWdqamJrb0ZFMGRCaDdLUkptNjBUN2hCVTg?oc=5" target="_blank">FDA clears Adicet Bio's application to study a gene-edited prostate cancer therapy</a>  <font color="#6f6f6f">Stock Titan</font>

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting
Business Wiregeneral

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting

<a href="https://news.google.com/rss/articles/CBMiywJBVV95cUxOTGFkN2dqMkxpM3hjT0NIUzlrX3RtVzJZNURhOTBNRWRSRTFSeXZxZUk0NDMwNXo3SUE0eGJoT3BfMHh2ZzVwMHdMTXlaazhod1JVZlIxbndyRE1ueGR4SmhEZVFON0hjMFJ0bHJsMkVGZmwyVTA2ZlZ4R3d4SlJFRDlKSTQ2U2U5SXJrdk9xUE1wWkdxQ3JVWnhHNzVYdUk3bmw4NkVWb0lMQmkxSHcwdzZHQWlWb2tzcVNRUzZ2UkMzSWNBa0hUa1R1OWdubFg5dUJQSUJ5MDB1MGZYRUc5TnVEeVdncXdmUnp1QlplV29jRUh2bzcyZ1BvNWVJNlp4c0d6YVc5b0luX1EyY2VBMWJJd01tTVVDRUJKTWE3bXNtUGNwSnFDSG80QVJsMWZIR0YwTTd0NTlTRnBGaktRVFF1WTgxd1NsbXlr?oc=5" target="_blank">Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting</a>  <font color="#6f6f6f">Business Wire</font>

Pfizer posts late-stage trial win for prostate cancer drug
Seeking Alphageneral

Pfizer posts late-stage trial win for prostate cancer drug

<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxPQkg0RTdlVE5DaDZ2bnJJOWtEQkxmT2J6QkQ2N1JmOUIzQWV5MUEtd1R0cXluRk1RZWFUTHdxUWJMeHhXQVNRdXVVbjA2Q2dIUExGRlVuel9tQWRzaEVhSXJMZkhGRDE0cmJxU2FUaDZMdVhLYmp3VWRaeVRZZnhka0YwbkxwQ2tUTm1FRlNaZ1NVU1lrYmtj?oc=5" target="_blank">Pfizer posts late-stage trial win for prostate cancer drug</a>  <font color="#6f6f6f">Seeking Alpha</font>

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat
GlobeNewswireworld

ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat

<a href="https://news.google.com/rss/articles/CBMixwJBVV95cUxPQXc2OUdkeDI0ODdJZjNGdUk1Q3BScmdXX20wTG01WGdlS1lXakg4Mjg4T0dRc1A5NlB6Q1FaZzBmNFVYdkRwUS1CcjdLd3RLT3ZiWlV1eVREc1hXTVFIY0FFWmJfV2kyTUtieFd4aHZwUENVcEhWazcxYWZUSWRGV1FVNmxnZjVKRWw0Yk53cE9IVUwwVVRnSmMyOGRRWlMxZXdpUzdDYmstUHpBVGNVbjB6WXlLZzdVdEZvNElRWkJSelh2ODM5dTFoYTJiUE5LT29TZ1lwNFNGbzN3RUJxVTkxeFZoR3JJam1PNjVWMWtqQ2FPZjZybnhmQTl2UHJlVVNuTE0tbzVXNy1JeV9HNTdINVZpQXVsdUkwT1doU3VIN0o2Ui1GYkdESm9xVFZlVk40UXBuQnVXUUptdWRLZkJjRGRCc0E?oc=5" target="_blank">ORIC® Pharmaceuticals Announces Preclinical Rinzimetostat</a>  <font color="#6f6f6f">GlobeNewswire</font>

Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026
Business Wiregeneral

Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026

<a href="https://news.google.com/rss/articles/CBMi4gJBVV95cUxQa2RsUUlwXy01R3FSS2NkYW9kMkpQWDNzeDM0eml1YktuanFwX0Q3YWJzN3dENUlMOU81Y3FNUmVaWkF5aDYxMDdtSWdjTzJtSldlMEFGb1VEa2dvYnpUZUt5ZnNWcEdtN05FeVJZVTNlM2otSUI5WS0tUGlOSlZDUmRId3pBNVEyNEY4ckJFMVluRVhIOEx1SWZ6QVZPbUtYQlpSa3d4b3FUVEhiVmRxMHZCczZhTzlFZndHNmRRYU5YX0Z1OS1ZdUtlbjVxU0tlVlY3MXRwU3NzMVhKb29mVl9NNWcyZzNqbmVULTlwWjk2dTVGaXkwVTlTSndfLWpyNTJkbjZVT3h2Q0pwQTI0TVVUbm1DVnpFMEZJRmxRdy0tMU0zbEZJY2Q2b0ZqeTAyZm5WVjlWMVJobGlzckVIRm9DelBTUVZMYjE1aW5sZmloZldiLUl2a2cxSE9qUTBwOFE?oc=5" target="_blank">Convergent Therapeutics to Present Largest Set of Prospective Phase 2 Data for an Alpha Radiopharmaceutical in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer at ASCO 2026</a>  <font color="#6f6f6f">Business Wire</font>

Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
grail.comgeneral

Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPTkFSQnVLNnYySWxGR0s5SmJHNE5IRENCYllvWDNRZUp1U05idnNoTDB5VlM4M1ZTMTRCUzliWkV3d1FIVGVZLXBKLW9YS0VFOXBUdUktbnZBU0lRM3lTaldxMmh1MHdkRTZsYnNSQkdMWmRQQzBFMzRvTDgwY1RfNHdoWjRNSklxUkRIdGIxNWJJUnZ5R21XdHd2M0dYeS0tVm9xN0NtakpFTEtOZ2I1ZGJvWUhEckhiaTBkd3VZTzJfZFNHNlBfOTRuZ25sZEpYUEtpeTgzc1k4Qk9zTGxoNkpfbTZWenViSmc?oc=5" target="_blank">Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology</a>  <font color="#6f6f6f">grail.com</font>

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer
PR Newswireworld

ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMiwAJBVV95cUxNOTZQRmdodEh6cEd5RXIyYnJDckVzTHlPeElaQUE1U0tTWjdZWlNOTGkxZWZlYmtrRGFCQkJVd3BtMkwtb2J1ZVozcnJpWGM4alZxeG9OaVNrU1V4OVRrbVhfbGllQ0Vzc1N0bXpyWmFpVEI5Rm9Xc0wxYzdHRVRpYWxiMlgya2JreGEzMER5d2J0clBaRXBlTjVfWFJhVmhSZThGZ3R2NEN2RUgyQkdua2hyY0d5Q09HVjlESk9MQVhQTkxuQVAyMi1uRkkyTnNnUU5zWnpINThYWlVLMXE3c1lMdnFWbGl4dm42MXZLeWxZNDlpOHlfR1BwdXo2LTFpc3M3dTVndlQwZ18tTk5UWlp5VXFwcFYtQ0VvSzU1ek5RRnpBelBlcFZ4cjNOaTRwdExyOUZHYnpIVC1lcGtVbg?oc=5" target="_blank">ARTBIO Announces Dosing of Two Cohorts with AB001 in ARTISAN, a Phase 1 Alpha Radioligand Therapy Clinical Trial for Metastatic Castration Resistant Prostate Cancer</a>  <font color="#6f6f6f">PR Newswire</font>

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer
WCM Newsroomgeneral

New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOZVV5Ym9xSEQtRUNqaFUwZTVPZjRUVEdGMjVtTi1KNVdZUVZOblVEQzg1Y1E3Z00xQWp6VUFpUUhJcVJpRmhMUHN2UTNkeG15ZUF3TjF5Wm42RlNyTmZKMFdNMjY2Y3lUS1h4Y1d4OFJSdkxheUF0eHZtN0loRHVGRWwzTXlqQ3lGZktTRV9hLWxvQm96Z09tcTl5YTZ3TDFUeGlJaDhER1FMNks5Z2VWc1hMMl9kQ3hod0pUX3dQeURfNUdGdkE?oc=5" target="_blank">New Radiopharmaceutical Shows Antitumor Activity in Patients with Advanced Prostate Cancer</a>  <font color="#6f6f6f">WCM Newsroom</font>

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer
Vir Biotechnologytech

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMi3AJBVV95cUxQdUhnMTFYSkFScGk3RVdIeFRXUUVmcTJ3eVNyTkEtbURaX09iQlBmZEFmdXZVVXB6SnBGMDY1d09HSjJ1a1ZWLVNxNzhmQVFVTlVNclVTRkZod0lILWNmREhsRUx6UHlCVE5qOUFwTnJoNlhHOXNNSUR1RTZaa2xIMll5Zlhzd05nUDJmZXNyNFNNbnRpQTY4MXZkQ0lrOUZKOFBJZlFHeTdaODFJd1JrRV85VnF4Qi1uc056S2lwOHNvNmVkQ1BnOC1TaWVRVV9UeGxoei16MTRrWWNTQ2M4TC1BTVVkSmdkWHlWSWxJcUhfMUVuX1pUZWg2UmdEQ2EwZVg5UUVpTENXVDhtUjRESmUtNXQzQjlnbUplcHBjbmpUYUJxOF8xRTFzeXFNUmxzNHdlcGpzZzVRdW1EUFVuTlhNT092alVuQTFGTDhMNnhuNFNFV2JaZkRJcms?oc=5" target="_blank">Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer</a>  <font color="#6f6f6f">Vir Biotechnology</font>

Curium Group, PeptiDream and PDRadiopharma Enroll First
GlobeNewswiregeneral

Curium Group, PeptiDream and PDRadiopharma Enroll First

<a href="https://news.google.com/rss/articles/CBMitgJBVV95cUxPeGZzSGZvU1Ftb1VOWm9VdE9tSjExcHk2OGxkQXdNeFptZWVUMDREeWJ1d3pGVzlDSjI2NGFSd01iUkIxTUN0N202TFFMR1lPenJBRzRsVEhfa0M5RXZoMVFPUUVSMDBMQVJaVmE4LXNLUmRwZWNIbU04UUROV3YwdXhJQnUxR2dybUh3UFBzekE4V3BOSGZqVHJaOFJzdHUzbnRJS0VSbFplbThTNzhhNTU5Q2N4anFXMVBrclJnMXg1OHQwTXMyU2h0ZGpVcm5lVjlHNVphSmhHeFEyY1RaSEszUWRxOExfdDdjUy1fbXcxbm9UN2xrY3ZXdUpLUEpEMXBGNmlzODZNMUVoSk52elprSFlhS0tibTNxR2NfZlloS3hBVTZtTVVQeUlZVk8tSG9DVUN3?oc=5" target="_blank">Curium Group, PeptiDream and PDRadiopharma Enroll First</a>  <font color="#6f6f6f">GlobeNewswire</font>

September Social Media Round-Up—Fast Company, Prostate Cancer Awareness Month, and More
Pfizerworld

September Social Media Round-Up—Fast Company, Prostate Cancer Awareness Month, and More

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxOaFNjbHFLTTQ1RldCdGxwbFNkMmFuajdTY3BxYWs1X1lvakpyWGRKcFJOVXhLSmROcTFMU0sxZVY2QkZ3Yk56eTM0cFg0a29CMjk1c1JRX1ZHQ1U4RDYwMmN5YnZqVlltZFIzSGY4d3UxQXZnV2w5REFsb3ZhaU1tVW1yV0VUdEk5Tno5QnFRbUktNnR6Nm9vbnE4UGk0MmJ4RmZDSlFIOXhsbWpGZl9KWW42cXE?oc=5" target="_blank">September Social Media Round-Up—Fast Company, Prostate Cancer Awareness Month, and More</a>  <font color="#6f6f6f">Pfizer</font>

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Business Wireworld

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)

<a href="https://news.google.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?oc=5" target="_blank">Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC)</a>  <font color="#6f6f6f">Business Wire</font>

FDA Approves IsoPSA® -- Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test
Business Wiregeneral

FDA Approves IsoPSA® -- Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxOVmtORkh2N2N2RUJaYzhrWmZXZGdLekV3Zm9SZE1SOTZzOWtrYm9GdnNQZ3ZHQ19fU18xb1llY3E0ZGNjSFVDbXZYZWxKWFVLTXN4d3NmdG0yeWRIUjlPT3lsOE5iUWZ2X1FyampROFVTMkdXdmdXVW93UmJLRTVKelVYaGREamFLUkM3R2VuT2lzM1YyVTdxdDRlamlNWm5QeER2U3NWSlVsQTMxcEtZRGtkaDNJY0p3T21LVUNabmo3dF9XUUVveXJkZEVCN3RmbHpERDByMA?oc=5" target="_blank">FDA Approves IsoPSA® -- Cleveland Diagnostics’ Novel Blood-Based Prostate Cancer Test</a>  <font color="#6f6f6f">Business Wire</font>

Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting
GRAILgeneral

Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

<a href="https://news.google.com/rss/articles/CBMixAJBVV95cUxPNFE3a2tkMTJpVjBOdm5YX0VOdTdRQ2NrQ0JxYXZUQ3ZoNzZYaWdiU29sdGZSemNGR1pfQl8zVEplMXAzcl9hUGdoZnJMT1dOWkdmUExIYkVnamJCa3dmRGllY3JCOHNVOFVyTVhGMDR0VFU3czJWb2FFbk12NTkzOG41eHlibURSNVhvUFgzSmNpb2M1dFRORS1ySHdpYnQ3S01SWE53THE3ZjNpWWJVZW1ublRmNmVTaFhLUlVndEV0NHZoMlFYTl9iNTVka08yTUV1U2tuTGk2NnNqUzNla2Y4LXI0UnBOZ1ZSVElZS05NT0MxREx3VlB2d1BXMjdrOFJVczRYVU4zcW5ReGdHQ1l1MWxfelRQVUJYVTdMWUNwUWNiMHg4Q1NDS0V4Sm0wc1MySzc2WFhoODFMYVYydGFHcHc?oc=5" target="_blank">Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting</a>  <font color="#6f6f6f">GRAIL</font>

Early-stage prostate cancer patients eligible for P100K subsidy
Cebu Daily Newsgeneral

Early-stage prostate cancer patients eligible for P100K subsidy

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPR0JNNmRDdlRLZ1RjQUU5c25FZkdGX21lZzB6ZmxNVllzdnZuc3dQRERqT2ktRFhIOF9TR3hJV3RsWnRJenhvbUtYNXR5QVhVa1diMDU3dWsxWDFsUkRjeWJPS0dvcERHbHZtVHlmNkJEWjlXY195Mk1VQkJHSG5lbEUzc3BmR0haR1VJVXRUdUxFd0I0OFB4eG94Z3JfN21Qb2dnSmFQVjTSAa4BQVVfeXFMTUQ2UU5Xc2x6NUtEdnQ0T1gxaVdadk12cUNrM0RIV3lzU1ZURnJOZjF0VlE0a0lkMXZ2X0d6VWhLbDE2Q0ZtcXlyM0tDR01zdXVVMnRJVHlZRC1MTnpZZnhnNERCTU5JTlAzRHdiTGRyZHpoajNQVVpUQ0RGcDBpejZ1TUpWdlRhRVhqb1ZsUVN3bjA3b2lqMUlQQkNVSndodUpGWElFeHdjMUV6SHJ3?oc=5" target="_blank">Early-stage prostate cancer patients eligible for P100K subsidy</a>  <font color="#6f6f6f">Cebu Daily News</font>

Enrollment goal met in trial of Vanquish device for localized prostate cancer
Urology Timesgeneral

Enrollment goal met in trial of Vanquish device for localized prostate cancer

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPTlBtQl9rU0dXSXdfVkx5V3F5UVdwaDZINXdadWo0aG5IdndSMVdaMzF2Sk0wU3Q5aFRobWJjaVF1YnY5XzVPcXI1TjUwUlhwWGt6RXZrcUxmbEhPOGwxR0FWTDYtM09vNXh1cUFTNktSRllsZjQtaVFvY1kxc1lCLVlxRWVzQjRSSTVwSHhUZngxWk1sWVo5WG5xazE1NXRiS0lWdkZZSDhobVFoal9RQQ?oc=5" target="_blank">Enrollment goal met in trial of Vanquish device for localized prostate cancer</a>  <font color="#6f6f6f">Urology Times</font>

Innovative targeted therapy halts prostate cancer spread to the bone
EurekAlert! Science News Releasesgeneral

Innovative targeted therapy halts prostate cancer spread to the bone

<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTE9WVk9RWUN0TlhzUUFtMGdjdk9hVWM4ajBMWDlnejlHVXU3c0lBTURLQWp0VVhGN1hPclQtX3dDckk2NWNvcXNDYWRZU1lBc0VxMUtud2h3MC04SG9x?oc=5" target="_blank">Innovative targeted therapy halts prostate cancer spread to the bone</a>  <font color="#6f6f6f">EurekAlert! Science News Releases</font>

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
AstraZenecageneral

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxQTVd2a2hRRWhHU0dMNEFQMlM4TUR2Yl9LQlVEM2lvSXg5Umc1SlQ5cjNZczlKX0hHQktaLVF2eEVRbElBQUp4ZjhBWFduYnhsMjBsTXBPcUp5dG05UzR4MlJyZTBpYVkzOHViblJPVFYxNkhsSG53bDI2VEU3aXpYSTJBbkNwM0pQQlU5X1VBWER0enlFRTJlM29LUQ?oc=5" target="_blank">AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer</a>  <font color="#6f6f6f">AstraZeneca</font>

Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer
AuntMinniegeneral

Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer

<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxNUkRlYmg4UWE3T3dRU09JZ0FSV215VFVjMG91RXNzblJlQVVSSkxabHdkRHpaOVdtTDRMSDdQOFV6SUFtRU0xcldnZjRzZUZ3NWxwU3Y0N1RYQU5qeWwybXZsSXlBRHdiNWhkUXBhbGJGcGhHUUhCdk1jdHc5bE1JY1RRd0loYWdsSGpwVl9sVUhBVVZnczh0SUZiV3pidjZ0QU1QOFk1QURQN0hJTWNlS1gzeWRPT01LbW1wNkRJaXNHWnFuTlk1WkpVSG9fM1NDZkRXQnd4NHdxLVdIc3ZIMDlCV1JJV01iT0ZEQ2dtRQ?oc=5" target="_blank">Lutetium-177 PSMA-617 shows promise in earlier-stage prostate cancer</a>  <font color="#6f6f6f">AuntMinnie</font>

Prostate Cancer Treatment Market Size to Reach USD 34.28 Billion by 2034
BioSpacemarkets

Prostate Cancer Treatment Market Size to Reach USD 34.28 Billion by 2034

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxNbERTUlVGUGVjSzZ0VHVnb1VfZ2JnNjVoVVF2dUhiWlJ6SFZhc3VyZjN0WUU5czJHY2tja0ZUQlJydl8ya0NRMmJ2OTVxck16Qk5WR0FQR3dUb2VYMm4xbURhSDhEamlXQ21SVzlDcGVCMVhLQXYxVUdiS29YM0UwUlc4Z0N0TGl3ai1wSDlaNXZXU3NVV1l2NDNDVng4VE8zeEdmeU5Vc2VMaW9kbE9qX0tn?oc=5" target="_blank">Prostate Cancer Treatment Market Size to Reach USD 34.28 Billion by 2034</a>  <font color="#6f6f6f">BioSpace</font>

FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels
CancerNetworkgeneral

FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels

<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxQUXo1LVg3aTlPOWx0VEVzVmI1bkJ1NnRKV0M4aXdkUHJCMFgtSzd6QmZmazVOY0s2anhDQ0l5R2JQVjJEZHU4M0h2OVgyMVpLVkRJSlpTOF9EdWlJNTlvWnFzaHhNTHRxdXAxMU5BajJuT0tIVDc1TG1VUzc3UHpENzhOV1hYTXVocE9XZFJLa2pDaGt0ZUVQN0Z5VFBRbmhERlI2Vk1QRzdYS2hKZm9r?oc=5" target="_blank">FDA Approves Novel Blood-Based Prostate Cancer Test for Elevated PSA Levels</a>  <font color="#6f6f6f">CancerNetwork</font>

Prostate Cancer Nodal Staging: Using Deep Learning to Predict
Naturegeneral

Prostate Cancer Nodal Staging: Using Deep Learning to Predict

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1CUC1Qbm51UzRSVnp1ZXRiV1hlc01INl9ybUJ3eFJyRW1XQzlETm9maG4zSVpaNVNabXU4SzlnUUNVMkx6d1dKOGp1Zm9ENVZ0Z2xYNjhuQ1prM1lUMzJV?oc=5" target="_blank">Prostate Cancer Nodal Staging: Using Deep Learning to Predict</a>  <font color="#6f6f6f">Nature</font>

FDA Grants Breakthrough Status to TriNetra-Prostate Blood Test to Detect Early-Stage Prostate Cancer
OncLivegeneral

FDA Grants Breakthrough Status to TriNetra-Prostate Blood Test to Detect Early-Stage Prostate Cancer

<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNckdqWnR4WTVzeUUyT2dINmJydWxMdTFvVXdSQ0ZSTzZ1TkQ5OVpUTEtmeG1WdktzTmJnV0pyU3d2Y09fYjJOXzFCS0dLY21VNHpoeXQ1OW5oM0hmWklFUkczUjV2bzg5N0htNDN1VW4tRFMtS3pESDNiTGNENEsyM0lkUkx3SE1Hci1DZVZXV0YwcDdfNm44UUFqODV6MWhOT0otOHdnSTZzcHR3Ti13WnJFR3ZOMURBNlA0b2Q3YXNIYlJ1TU8ybg?oc=5" target="_blank">FDA Grants Breakthrough Status to TriNetra-Prostate Blood Test to Detect Early-Stage Prostate Cancer</a>  <font color="#6f6f6f">OncLive</font>

"Prostate Cancer Stage Inc" — Live Google News Trends & Headlines